Comparison between high and low molecular weight hyaluronates in knee osteoarthritis patients: Open-label, randomized, multicentre clinical trial

Journal of International Medical Research

Volumn 34, Issue 1, 2006, Pages 77-87

  Lee, P B ^a   Kim, Y C ^a   Lim, Y J ^a   Lee, C J ^a   Sim, W S ^b   Ha, C W ^b   Bin, S I ^c   Lim, K B ^d   Choi, S S ^e   Lee, S C ^a  

^a Seoul National University College of Medicine   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

^c University of Ulsan College of Medicine   (South Korea)

^d Inje University College of Medicine   (South Korea)

^e Korea University College of Medicine   (South Korea)

Author keywords

Adults; High molecular weight; Hyaluronate; Knees; Low molecular weight; Osteoarthritis; WOMAC likert scores

Indexed keywords

C REACTIVE PROTEIN; HIGH MOLECULAR WEIGHT HYALURONIC ACID; HYAL; HYALURONIC ACID; HYRUAN PLUS; LOW MOLECULAR WEIGHT HYALURONIC ACID; PARACETAMOL; UNCLASSIFIED DRUG;

ADULT; AGED; ANALGESIC ACTIVITY; ARTHRALGIA; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; INJECTION SITE PAIN; JOINT SWELLING; KNEE FUNCTION; KNEE OSTEOARTHRITIS; LEG PAIN; LEUKOPENIA; MALE; MOLECULAR WEIGHT; MULTICENTER STUDY; MYALGIA; OPEN STUDY; OSTEOARTHRITIS; PAIN ASSESSMENT; PARESTHESIA; PROTEIN BLOOD LEVEL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SELF REPORT; URTICARIA; VISUAL ANALOG SCALE; WEIGHT BEARING;

EID: 33645280054     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323000603400110     Document Type: Article

References (19)

1. Balazs EA, Watson D, Huff IF, Roseman S: Hyaluronic acid in synovial fluid. I. Molecular parameters of hyaluronic acid in normal and arthritis human fluids. Arthritis Rheum 1967; 10: 357-376.
2. Dahl LB, Dahl IM, Engstrom-Laurent A, Granath K: Concentration and molecular weight of sodium hyaluronate in synovial fluid from patients with rheumatoid arthritis and other arthropathies. Ann Rheum Dis 1985; 44: 817-822.
3. Lo GH, LaValley M, McAlindon T, Felson DT: Intra-articular hyaluronic acid in treatment of knee osteoarthritis: a meta-analysis. JAMA 2003; 290: 3115-3121.
4. Marshall KW: Intra-articular hyaluronan therapy. Curr Opin Rheumatol 2000; 12: 468-474.
5. Uebelhart D, Williams JM, Uebelhart D, Williams JM: Effects of hyaluronic acid on cartilage degradation. Curr Opin Rheumatol 1999; 11: 427-435.
6. Kikuchi T, Yamada H, Shimmei M: Effect of high molecular weight hyaluronan on cartilage degeneration in a rabbit model of osteoarthritis. Osteoarthritis Cartilage 1996; 4: 99-110.
7. Sakakibara Y, Miura T, Iwata H, Kikuchi T, Yamaguchi T, Yoshimi T, et al. Effect of high-molecular-weight sodium hyaluronate on immobilized rabbit knee. Clin Orthop Relat Res 1994; 299: 282-292.
8. Yoshimi T, Kikuchi T, Obara T, Yamaguchi T, Sakakibara Y, Itoh H, et al: Effects of high-molecular-weight sodium hyaluronate on experimental osteoarthrosis induced by the resection of rabbit anterior cruciate ligament. Clin Orthop Relat Res 1994; 298: 296-304.
9. Gomis A, Pawlak M, Balazs EA, Schmidt RF, Belmonte C: Effects of different molecular weight elastoviscous hyaluronan solutions on articular nociceptive afferents. Arthritis Rheum 2004; 50: 314-326.
10. Lussier A, Cividino AA, McFarlane CA, Olszynski WP, Potashner WJ, De Medicis R: Viscosupplementation with hylan for the treatment of osteoarthritis: findings from clinical practice in Canada. J Rheumatol 1996; 23: 1579-1585.
11. Wobig M, Dickhut A, Maier R, Vetter G: Viscosupplementation with hylan G-F 20: a 26-week controlled trial of efficacy and safety in the osteoarthritic knee. Clin Ther 1998; 20: 410-423.
12. Wobig M, Bach G, Beks P, Dickhut A, Runzheimer J, Schwieger G, et al: The role of elastoviscosity in the efficacy of viscosupplementation for osteoarthritis of the knee: a comparison of hylan G-F 20 and a lower-molecular-weight hyaluronan. Clin Ther 1999; 21: 1549-1562.
13. Adams ME, Atkinson MH, Lussier AJ, Schulz JI, Siminovitch KA, Wade JP, et al: The role of viscosupplementation with hylan G-F 20 (Synvisc) in the treatment of osteoarthritis of the knee: a Canadian multicentre trial comparing hylan G-F 20 alone, hylon G-F 20 with non-steroidal anti-inflammatory drugs (NSAIDS) and NSAIDs alone. Osteoarthritis Cartilage 1995; 3: 213-225.
14. Adams ME: An analysis of clinical studies of the use of crosslinked hyaluronan, hylan, in the treatment of osteoarthritis. J Rheumatol Suppl 1993; 39: 16-18.
15. Aviad AD, Houpt JB: The molecular weight of therapeutic hyaluronan (sodium hyaluronate): how significant is it? J Rheumatol 1994; 21: 297-301.
16. Laurent TC, Fraser JR: Hyaluronan. FASEB J 1992; 6: 2397-2404.
17. Ghosh P, Guidolin D: Potential mechanism of action of intra-articular hyaluronan therapy in osteoarthritis: are the effects molecular weight dependent? Semin Arthritis Rheum 2002; 32: 10-37.
18. Fraser JR, Laurent TC, Laurent UB: Hyaluronan: its nature, distribution, functions and turnover. J Intern Med 1997; 242: 27-33.
19. Altman RD, Moskowitz R: Intraarticular sodium hyaluronate (Hyalgan) in the treatment of patients with osteoarthritis of the knee: a randomized clinical trial. Hyalgan Study Group. J Rheumatol 1998; 25: 2203-2212.